Consumer health is not immune
Haleon's Q1 2026 results flagged ongoing private-label pressure in mainstream pain relief. That is a category where brand trust and efficacy claims have historically given national brands a durable moat. The fact that private label is making inroads there tells you the pressure is no longer confined to commodity grocery categories like ambient cooking ingredients or household cleaning.
Consumer health is a high-stakes front for private-label competition because margin profiles are better than food, and retailer own-brand quality in OTC has improved substantially. If you run a national brand in vitamins, pain relief, or digestive health, the premium PL tier in pharmacies and grocery health aisles deserves the same competitive scrutiny you would give a challenger brand.
The cost environment makes retailer brands structurally more attractive
A second wave of cost inflation is arriving, and it reinforces private-label dynamics rather than easing them. Across India, crude-linked raw materials including polymers and specialty resins used in packaging have jumped 60 to 70 percent since the start of the Iran war, according to sector executives. Companies including Dabur, Britannia, and HUL are responding with price increases of 2 to 5 percent and, in some cases, grammage reductions.
In that environment, national-brand prices go up and packs get smaller. Retailer brands, which carry lower marketing cost structures and tighter supply chains, have more room to hold price or absorb cost without the same visible impact on the consumer. That asymmetry in cost pass-through is one of the structural reasons private-label share tends to accelerate during inflationary episodes rather than just hold.
Post Holdings' incoming CEO Nicolas Catoggio has already signalled that if inflation stays in the low-single-digits, CPGs are more likely to absorb costs within their P&L by lowering promotional intensity rather than raising prices. Pulling back on promotions shrinks one of the main reasons a price-sensitive shopper ever reaches for the national brand in the first place. If the deal disappears, so does the rationale for the trade-up.
What retailers are doing with the opportunity
Retailers are not sitting still. The strategic sophistication of own-brand development has accelerated, and the NPD pipeline inside major retailer brand programmes now rivals what mid-size national brands can bring to market. M&S Food's Collection tier, for example, runs seasonal NPD cycles that are specifically designed to sit at a quality perception level above the national brand standard in the same category. Trader Joe's has built a store format around exclusive own-brand product in a way that makes the private-label choice not just acceptable but the point of the shopping trip.
Lidl's Deluxe range applies the same logic in a hard-discount format, which is a particularly powerful combination. The shopper is already in a store built for value, and the premium PL tier within it gives them a quality trading-up moment that keeps their full basket inside the store. For national brands, that means competing not only against the standard own-label alternative but against a curated premium tier sitting inside a channel they may be absent from entirely.
What to watch next, and what to do this week
Three things are worth tracking closely through the rest of 2026.
First, watch how retailers use cost inflation as a timing opportunity. When national brands raise prices, retailers with established premium own-brand programmes will use the gap to trial new shoppers on their top-tier lines. The conversion data from those trial windows will shape ranging decisions into 2027.
Second, monitor NPD share. Private-label new product development has historically lagged national brands on innovation speed. That gap is closing, particularly in food and consumer health. If retailer own-brand NPD starts appearing in premium and functional segments ahead of national brand launches, the quality perception argument weakens further.
Third, be honest about where your brand actually sits relative to the premium PL tier in your category. The relevant question is not whether you beat the standard own-label product on quality. Almost every national brand does. The question is whether the shopper can feel a meaningful difference between your product and the retailer's premium line when they taste, use, or experience it. If the answer is uncertain, that is the work to do now, not at the next strategy review.
Price, pack, and claim architecture all need to be audited against the premium PL benchmark in your category, not just against standard own-label. The brands that wait for retailer share to stop growing before acting are already behind.